Medtronic invests in Pi-Cardia to boost complex TAVR innovation

0 min read | Published on 01 Sept 2026, 04:25 PM |Updated on 01 Sept 2026, 04:25 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Medtronic plc announces strategic investment in Pi-Cardia Ltd
Deal secures option to strengthen structural heart portfolio
Focus is on complex transcatheter aortic valve replacement
Aims to accelerate innovation for complex TAVR patients

*this image is generated using AI for illustrative purposes only.

Medtronic plc (NYSE: MDT) has announced a strategic investment in Pi-Cardia Ltd. The deal secures an option for Medtronic to strengthen its structural heart portfolio, targeting innovations for complex transcatheter aortic valve replacement (TAVR) patients.

Pi-Cardia is a pioneer in leaflet modification technologies for structural heart disease. The investment focuses on addressing the evolving needs of increasingly complex TAVR procedures and patient profiles.

Strategic Rationale

The partnership supports the next generation of innovation in structural heart care. By securing this option, Medtronic aims to enhance its capabilities in treating patients with more complex anatomical challenges during TAVR interventions.

What the Numbers Show

The source material does not disclose specific financial terms, such as the investment amount or equity stake acquired. Consequently, no quantitative analysis of valuation or immediate financial impact can be derived from the filing.

How might this investment accelerate Medtronic's pipeline for treating high-risk TAVR patients compared to competitors like Edwards Lifesciences?

What are the potential regulatory hurdles and timelines for integrating Pi-Cardia's leaflet modification technology into Medtronic's existing valve systems?

Could this strategic option lead to a full acquisition of Pi-Cardia, and how would that impact Medtronic's R&D spending and balance sheet in the medium term?

Medtronic Q2 earnings preview: EPS forecast $1.39, revenue $9.54 billion

1 min read | Published on 28 Aug 2026, 03:41 PM |Updated on 28 Aug 2026, 03:41 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Medtronic reports Q2 earnings on Sept 1; EPS expected at $1.39 vs $1.26 prior year
Consensus revenue estimate stands at $9.54 billion, up from $8.54 billion last year
Board declared a 72-cent per share cash dividend for the second quarter
UBS upgraded stock to Buy with $100 price target; Needham raised target to $114
Shares closed at $89.97 on Thursday, down 2.2%

*this image is generated using AI for illustrative purposes only.

Medtronic plc (NYSE: MDT) will release its second-quarter earnings before the market opens on Tuesday, Sept. 1. The Galway, Ireland-based medical technology company is expected to report quarterly earnings per share (EPS) of $1.39, an increase from $1.26 in the year-ago period.

Consensus estimates project quarterly revenue of $9.54 billion, compared to $8.54 billion reported last year. On Aug. 20, the board declared a cash dividend of 72 cents per ordinary share for the second quarter.

Medtronic shares fell 2.2% to close at $89.97 on Thursday.

Analyst Ratings and Price Targets

Several highly accurate analysts have recently revised their outlook for Medtronic:

Needham analyst Mike Matson maintained a Buy rating and raised the price target from $101 to $114 on Aug. 27, 2026. His accuracy rate is 58%.
BTIG analyst Ryan Zimmerman maintained a Buy rating with a price target of $91 on Aug. 18, 2026. His accuracy rate is 65%.
UBS analyst Priya Sachdeva upgraded the stock from Neutral to Buy and raised the price target from $85 to $100 on July 28, 2026. Her accuracy rate is 67%.
TD Cowen analyst Joshua Jennings maintained a Buy rating but cut the price target from $119 to $100 on July 10, 2026. His accuracy rate is 57%.
Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and cut the price target from $106 to $105 on July 6, 2026. His accuracy rate is 64%.

What the Numbers Show

The consensus revenue estimate of $9.54 billion implies a significant growth trajectory from the prior year’s $8.54 billion. Simultaneously, the EPS forecast of $1.39 represents a notable improvement over the previous year’s $1.26, suggesting analysts anticipate margin expansion or efficiency gains alongside top-line growth.

How might Medtronic's recent strategic acquisitions impact its integration costs and long-term margin expansion in the upcoming quarters?

Given the divergence in analyst price targets ranging from $91 to $114, what specific operational metrics will be the primary drivers for investors to favor the higher-end valuations?

Will the projected 11.7% revenue growth be sustained across all major therapeutic areas, or is it heavily reliant on specific high-growth segments like diabetes care or cardiovascular solutions?